Adenocarcinoma of prostate
Item
histologically proven adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Diagnosis Sextant biopsy | Diagnosis Biopsy Quantity
Item
diagnosed by sextant or greater biopsy
boolean
C0011900 (UMLS CUI [1,1])
C3846092 (UMLS CUI [1,2])
C0011900 (UMLS CUI [2,1])
C0005558 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Disease TNM clinical staging
Item
clinical stage < t3 (stage i or ii) disease
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Prostate specific antigen measurement
Item
prostate-specific antigen < 20.0 ng/ml
boolean
C0201544 (UMLS CUI [1])
Gleason score
Item
gleason score < 8
boolean
C3203027 (UMLS CUI [1])
Prostatectomy Scheduled | Brachytherapy Scheduled
Item
scheduled to undergo prostatectomy or brachytherapy
boolean
C0033573 (UMLS CUI [1,1])
C0205539 (UMLS CUI [1,2])
C0006098 (UMLS CUI [2,1])
C0205539 (UMLS CUI [2,2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Life Expectancy
Item
life expectancy > 5 years
boolean
C0023671 (UMLS CUI [1])
Exclusion | Cancer Other | Exception Skin carcinoma
Item
no other prior malignancy (excluding nonmelanoma skin cancer) in the past 5 years
boolean
C2828389 (UMLS CUI [1])
C1707251 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
Finasteride | Selenomethionine | Placebo
Item
willing and able to take finasteride, selenomethionine, and/or placebo for 3-5 weeks prior to prostatectomy/brachytherapy
boolean
C0060389 (UMLS CUI [1])
C0036584 (UMLS CUI [2])
C1696465 (UMLS CUI [3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Finasteride Previous | Dutasteride Previous | Serenoa repens extract Previous | Saw palmetto extract Previous | 5-alpha Reductase Inhibitors Previous
Item
more than 1 year since prior finasteride, dutasteride, sereona repens (saw palmetto), or any other 5-α reductase inhibitor
boolean
C0060389 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0754659 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C3491902 (UMLS CUI [3,1])
C0205156 (UMLS CUI [3,2])
C0771607 (UMLS CUI [4,1])
C0205156 (UMLS CUI [4,2])
C2936788 (UMLS CUI [5,1])
C0205156 (UMLS CUI [5,2])
Exclusion Criteria | Hormone Therapy | Therapeutic radiology procedure
Item
no prior hormonal therapy or radiotherapy
boolean
C0680251 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
Exclusion Criteria | Study Subject Participation Status Involving Therapeutic intervention | Study Subject Participation Status Involving Surgical intervention | Study Subject Participation Status Involving Nutritional Intervention | Study Subject Participation Status Involving Life Style Intervention | Dietary Modification | Exercise
Item
more than 30 days since prior and no concurrent participation in any other clinical trial involving a medical, surgical, nutritional, or life-style intervention (e.g., dietary modification or exercise)
boolean
C0680251 (UMLS CUI [1])
C2348568 (UMLS CUI [2,1])
C1314939 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C2348568 (UMLS CUI [3,1])
C1314939 (UMLS CUI [3,2])
C0549433 (UMLS CUI [3,3])
C2348568 (UMLS CUI [4,1])
C1314939 (UMLS CUI [4,2])
C1882127 (UMLS CUI [4,3])
C2348568 (UMLS CUI [5,1])
C1314939 (UMLS CUI [5,2])
C0023676 (UMLS CUI [5,3])
C0184661 (UMLS CUI [5,4])
C0086153 (UMLS CUI [6])
C0015259 (UMLS CUI [7])
Exclusion Criteria | Selenium supplement Dose U/day | Multivitamin Supplements
Item
no concurrent selenium dietary supplement at doses > 200 mg/day, including multivitamin supplements
boolean
C0680251 (UMLS CUI [1])
C0521939 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0301532 (UMLS CUI [3,1])
C0242295 (UMLS CUI [3,2])
Selenium supplement Previous U/day
Item
at least 30 days since > 200mg/day of prior selenium dietary supplement
boolean
C0521939 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
Exclusion Criteria | Hormone Therapy | 5-alpha Reductase Inhibitors | Finasteride | Dutasteride | Androgen Antagonists | bicalutamide | Flutamide | Ketoconazole | Luteinizing Hormone-releasing Hormone Agonist | Leuprolide Acetate | Goserelin Acetate | abarelix
Item
no other concurrent hormonal therapy, including 5-α reductase inhibitors (e.g., finasteride or dutasteride); anti-androgens (e.g., bicalutamide, flutamide, or ketoconazole); or luteinizing hormone-releasing hormone agonists (e.g., leuprolide acetate, goserelin acetate, or abarelix)
boolean
C0680251 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C2936788 (UMLS CUI [3])
C0060389 (UMLS CUI [4])
C0754659 (UMLS CUI [5])
C0002842 (UMLS CUI [6])
C0285590 (UMLS CUI [7])
C0016384 (UMLS CUI [8])
C0022625 (UMLS CUI [9])
C1518041 (UMLS CUI [10])
C0700596 (UMLS CUI [11])
C0700476 (UMLS CUI [12])
C0965390 (UMLS CUI [13])